Treatment with anti-tumor necrosis factor ⍺ (TNF-⍺) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions - 05/09/11
Abstract |
We treated a 57-year-old woman for refractory inflammatory bowel disease with a humanized anti–tumor necrosis factor ⍺ monoclonal antibody (Infliximab). The patient also had a 15-year history of Crohn’s disease and a 20-year history of moderate to severe psoriasis. She received a single infusion of Infliximab (5 mg/kg). Two weeks after the infusion her psoriasis had dramatically improved in appearance. To our knowledge, our case is the first reported instance of successful anti–tumor necrosis factor ⍺ therapy in psoriasis. (J Am Acad Dermatol 2000;42:829-30.)
Le texte complet de cet article est disponible en PDF. Reprint requests: Alice B. Gottlieb, MD, PhD, Clinical Research Center, One Robert Wood Johnson Place, Box 19, New Brunswick, NJ 08903. E-mail: gottliab@umdnj.edu. |
Vol 42 - N° 5P1
P. 829-830 - mai 2000 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?